COMMUNIQUÉS West-GlobeNewswire

New phantom share-based incentive program
04/06/2018
Orphazyme A/S Company announcement No. 07/2018 Copenhagen, June 4, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that the [...]
Shire plc : Rule 2.9 Announcement
04/06/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 4 June 2018 Shire [...]
CMR Surgical raises $100 million in a Series B financing
04/06/2018
CMR Surgical Limited ("CMR Surgical" or the "Company") CMR Surgical raises $100 million in a Series B financing Europe’s largest medical device financing paves way to Versius ® commercialisation Cambridge, UK, 4 June [...]
ERYTECH to Present Pharmacodynamic Data from Phase 2/3 Trial of Eryaspase in ALL at ASCO 2018
04/06/2018
LYON, France, June 04, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances [...]
INNATE PHARMA : Data from Phase I of monalizumab and durvalumab in MSS-CRC at ASCO 2018
04/06/2018
CLINICAL DATA FROM ONGOING PHASE I DOSE ESCALATION AND EXPANSION STUDY OF MONALIZUMAB AND IMFINZI ® (DURVALUMAB) IN COLORECTAL cancer PATIENTS PRESENTED AT 2018 ASCO annual meeting Updated clinical data show preliminary [...]
INNATE PHARMA : Données de Phase I avec monalizumab et durvalumab dans le MSS-CRC présentées au congrès ASCO
04/06/2018
Données cliniques d'un essai de Phase I évaluant monalizumab et Imfinzi® (durvalumab) chez des patients atteints d'un cancer colorectal présentées au congrès annuel de l'ASCO 2018 Les données cliniques mises à jour [...]
MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®
04/06/2018
PORTLAND, Ore. and CARLSBAD, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation and Genoptix, Inc. announced today that they have entered into an exclusive agreement to market and perform diagnostic [...]
FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting
04/06/2018
Demonstrates Enhanced Rate of Surgical Resection with Pamrevlumab in Patients with Previously Unresectable Disease SAN FRANCISCO, June 03, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical [...]
Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers
04/06/2018
Companies to Start Phase 1/2 Study to Evaluate the Combination of Rubraca ® (Rucaparib) and Sacituzumab Govitecan in Patients with Metastatic Triple-negative Breast Cancer and Metastatic Urothelial Cancer BOULDER, Colo [...]
Shire plc : New Data on the Cardiovascular Safety of Prucalopride Presented at 2018 Digestive Disease Week Annual Meeting
03/06/2018
New Data on the Cardiovascular Safety of Prucalopride Presented at 2018 Digestive Disease Week Annual Meeting New data from this observational, pharmacoepidemiology safety study included more than 35,000 patients (> [...]
IMV Inc. (Formerly Immunovaccine Inc.) Presents New Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ASCO Meeting
03/06/2018
Combination Immunotherapy Continues to Show Tolerable Safety Profile and Promising Activity With Second Dosing Cohort Showing 6 of the First 8 Evaluable Participants Exhibiting Stable Disease at First CT Scan Tumor [...]
Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer
03/06/2018
Confirmed Overall Response Rate of 31 Percent; with Median Duration of Response of 7.4 Months and Median Progression-free Survival of 6.8 Months CHICAGO, June 03, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (NASDAQ: [...]
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
03/06/2018
Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line postmenopausal patients with HR+/ [...]
Epizyme Presents Encouraging Phase 2 Data of Tazemetostat for Malignant Mesothelioma at ASCO
03/06/2018
Disease Control Rate of 51 Percent Achieved at 12 Weeks Represents the First Reported Clinical Data of an EZH2 Inhibitor in Patients with Relapsed/Refractory Malignant Mesothelioma CAMBRIDGE, Mass., June 03, 2018 (GLOBE [...]
TLC Submits IND to US FDA Application for TLC178, Liposomal Vinorelbine Candidate for Pediatric Rhabdomyosarcoma
03/06/2018
TAIPEI, Taiwan, June 03, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel [...]
Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting
02/06/2018
-- CDX-3379 also featured in a “clinical trials in progress” presentation -- HAMPTON, N.J., June 02, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented two programs at the 2018 American [...]
Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent
02/06/2018
- In 179 Relapsed or Refractory IDH1m AML Patients, Primary Endpoint of CR+CRh Rate of 31.8% with a Median Duration CR+CRh of 8.2 Months - - Updated Data Suggest that R/R AML Patients with IDH1-Mutation Clearance Who [...]
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
02/06/2018
ENESTop and ENESTfreedom data evaluate Treatment-free Remission (TFR) rates at 144 weeks among eligible Ph+ CML-CP patients who stopped Tasigna ® Findings further support durability and safety of TFR with Tasigna; [...]
Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers
02/06/2018
Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., June 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and [...]

Pages